TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients evaluated with osteoarthritis who are surgical candidates for ankle fusion or total ankle replacement.~* Registered patients at Mayo Clinic in Florida with scheduled visit to see Dr.Whalen~Exclusion Criteria:~* Patients with lower extremity diabetic neuropathy~* History of prior trauma of ankle with residual nerve injury~* Current medication of pregabalin or gabalin~* Allergy to lidocaine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Saphenous nerve block (Type: None): Data collection after saphenous nerve block placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Beta-blockers in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* WHO category 1 pulmonary arterial hypertension (Nice 2013)~* WHO functional class II-III~* RVEF by cardiac MRI \< 45%~* Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and functional class in the past 3 months. Patient can be on either mono or combination PAH-specific therapy~Exclusion Criteria:~* Subjects will be excluded from participation in the study if any of the following conditions exist:~* Significant persistent bradycardia (resting heart rate \< 60 bpm) without a permanent pacemaker~* Second or third degree AV block without a permanent pacemaker~* Significant sinus tachycardia (resting heart rate \> 110 bpm)~* Use of anti-arrhythmic drugs~* Hypotension defined as systolic blood pressure \< 100 mmHg at the time of enrollment~* Significant illness in the past 30 days requiring hospitalization~* Acute decompensated right heart failure within past 30 days~* Known allergy or intolerance to carvedilol or other β blockers~* Cardiac index \< 2 l/min/m2 or right atrial pressure \> 15 mm Hg by right heart catheterization within last 3 months~* Asthma~* Positive pregnancy test in patients of child bearing-potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carvedilol First (Type: EXPERIMENTAL): Crossover Design: Participants receive Carvedilol first and placebo second
- Placebo First (Type: PLACEBO_COMPARATOR): Crossover Design: Participants receive placebo first and Carvedilol second

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age less than or equal to 34 weeks~* Postnatal age less than or equal to 7 days (168 hours).~* Assisted ventilation for hypoxemic respiratory failure.~* Diagnosis of NHRF including perinatal aspiration syndrome (meconium, blood, or amniotic fluid), suspected/proven pneumonia/sepsis, respiratory distress syndrome, idiopathic persistent pulmonary hypertension of the newborn (PPHN) or suspected pulmonary hypoplasia.~* Receiving INO for at least 1 hour and not \>72 hours.~* Oxygenation Index (OI ) ≥ 15 on any 2 arterial blood gases 15 minutes to 12 hours apart while on INO.~* An indwelling arterial line is present~Exclusion Criteria:~* Any infant in whom a decision has been made not to provide full treatment (e.g. chromosomal anomalies, severe birth asphyxia).~* Known structural congenital heart disease except patent ductus arteriosus and atrial/ventricular level shunts.~* Congenital diaphragmatic hernia.~* Thrombocytopenia unresponsive to platelet transfusion.~* Enrollment in a conflicting and/or Investigational New Drug (IND) clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Inhaled PGE1 (150 ng/kg/min) (Type: ACTIVE_COMPARATOR): 150 ng/kg/min Inhaled PGE1
- Aerosolized Normal Saline (Type: PLACEBO_COMPARATOR): Eligible infants will be randomly assigned to either IPGE1 \[150ng/kg/min\], IPGE1 \[300ng/kg/min\] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
- Inhaled PGE1 (300 ng/kg/min) (Type: ACTIVE_COMPARATOR): 300 ng/kg/min of Inhaled PGE1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Post-tonsillectomy Pain Control in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* Surgical indications: Chronic tonsillitis, Snoring, Sleep apnea~* Surgical procedure: Tonsillectomy with monopolar cautery, hemostasis with monopolar cautery and/or suction cautery. The surgical procedure can also include Adenoidectomy with suction cautery~Exclusion Criteria:~* Additional surgical procedures (i.e. UPPP (uvulopalatopharyngoplasty), septoplasty, inferior turbinate reduction) during same surgery~* Pregnant females~* Indications: Suspected malignancy~* History of chronic pain or daily pain medication used for another medical problem~* History of liver disease~* Contraindications to preoperative Decadron~* Contraindications to pain regimen medications (Tylenol, Norco, Percocet, Dilaudid)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tonsillectomy and Norco (Type: ACTIVE_COMPARATOR): This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
- Tonsillectomy and Percocet (Type: ACTIVE_COMPARATOR): This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
- Tonsillectomy and Dilaudid + Tylenol (Type: ACTIVE_COMPARATOR): This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient admitted to a Danish emergency department, lung medical department or medical department~* Age \>18 years~* Hospitalized \<48 hours~* Positive COVID-19 test/diagnosis during the hospitalization~* Signs informed consent~Exclusion Criteria:~* If the patient uses \> 5 LO2/min at time of recruitment~* Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates~* Pregnancy~* Breastfeeding~* Neurogenic hearing loss~* Psoriasis~* Retinopathy~* Maculopathy~* Changes in vision field~* Severe liver disease other than amoebiases~* Severe gastrointestinal, neurological or haematological disorders~* eGFR \< 45 ml/min/1.73m2~* Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval~* Myasthenia Gravis~* Uses Digoxin~* Glucose-6-phosphate dehydrogenase deficiency~* Porphyria~* Hypoglycemia at any time since hospitalization~* Severe mental illness which significantly impedes cooperation~* Severe linguistic problems that significantly impedes cooperation~* Treatment with sickle alkaloids

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2
- Intervention (Type: ACTIVE_COMPARATOR): This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Percutaneous Cochlear Implantation: Implementation of Technique

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 year old patients undergoing cochlear implantation who are able to participate in the informed consent process.~* Pre-operative CT scan of head performed as standard of care for cochlear implant work-up.~Exclusion Criteria:~* Patients with co-morbidities so severe that the potential additional operating room time is deemed to be too significant of an operative risk. This assessment is made by the local institutions pre-operative work-up.~* History of allergic reaction/intolerance of local anesthesia and/or epinephrine.~* History of allergic reaction to titanium.~* Patients with severe anatomical abnormality of the temporal bone.~* Patients with severe chronic ear disease for whom traditional mastoidectomy might offer benefit.~* Females who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Use of image guided surgery (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Prescribed a new anti-arrhythmic medication for atrial fibrillation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phone follow-up (Type: EXPERIMENTAL): All study participants will be receiving education and monthly telephone follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Three Oral Devices as Mouthguard in Electroconvulsive Therapy. Randomized Crossover Clinical Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should have an intellectual level that allows a proper communication and must agree to cooperate in all tests and exams required by the study protocol.~* Obtaining written informed consent for participating in the project (model consent form)~* The patient must have enough teeth in the upper arch or being a carrier of a stable removable prosthesis.~Exclusion Criteria:~* Being in a maintenance ECT program.~* Receiving ECT during the six months prior to the index episode.~* Pregnancy and lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sequence SB-CA-SM (Type: EXPERIMENTAL): Solubrux®+ Customized Appliance + Somatics®
- Sequence SB-SM-CA (Type: EXPERIMENTAL): Solubrux®+Somatics®+Customized Appliance
- Sequence CA-SB-SM (Type: EXPERIMENTAL): Customized Appliance+Solubrux®+Somatics®
- Sequence CA-SM-SB (Type: EXPERIMENTAL): Customized Appliance+Somatics®+Solubrux®
- Sequence SM-SB-CA (Type: EXPERIMENTAL): Somatics®+Solubrux®+Customized Appliance
- Sequence SM-CA-SB (Type: EXPERIMENTAL): Somatics®+ Customized Appliance+Solubrux®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of androgen-independent prostate cancer~  * Osteoblastic metastases~ * No predominant visceral metastases~* Progressive disease after response to prior induction chemotherapy (prostate-specific antigen decline of at least 50% from baseline after 16 weeks of treatment)~* No symptomatic lymphadenopathy (i.e., scrotal or pedal edema)~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Adequate physiologic reserves~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* No prior radionuclide therapy~Surgery~* Not specified~Other~* No more than 3 prior cytotoxic treatments~* More than 6 months since prior celecoxib or rofecoxib

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: Celecoxib (Type: EXPERIMENTAL): Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
- Arm II: No Celecoxib (Type: EXPERIMENTAL): Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Age \>=20 and \<=75~2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, tubal cancer~3. Stage 3 or 4~4. WBC \>= 3500/mm3, ANC \>= 1500/mm3, platelet \>= 100000/mm3, hemoglobin \>= 10 g/dl~5. Serum creatinine \<= upper normal limit \* 1.25~6. Total bilirubin \<= 1.5mg/mm3, ALT/AST \<= upper normal limit \* 3, ALP \<= upper normal limit \* 3~7. Adequate compliance and geographical closeness which make adequate follow-up possible~8. GOG performance status 0-2~9. Anticipated survival \>= 3 months~10. Who agreed to participate in this study and signed on informed consent form~Exclusion criteria:~1. History of chemotherapy or radiotherapy on abdomen/pelvis area~2. Pleural/pericardial effusion, ascites causing respiratory difficulties \>= NCI-CTCAE grade 2~3. History of other cancers within 5 years~4. History of unapproved therapy within 30 days before enrollment~5. Other serious diseases which could threat the safety of participants or impair the ability of participants to complete the participation.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IP Chemotherapy (Type: EXPERIMENTAL): Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Static vs. Articulating Antibiotic Spacer for Periprosthetic Joint Infection in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Male or female age 18 to 100 years of age.~2. Preoperative diagnosis of bacterial infection by culture which would include a preoperative aspiration and at least three intraoperative cultures. The preoperative aspiration would also be sent for a cell count with differential. All patients would have an erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) drawn in the preoperative phase. Patients with a negative preoperative aspiration, but an actively draining wound or draining sinus tract, would be considered as infected. Intraoperative histopathology would also be obtained in all cases of infected total knee replacement at the time of the resection.~3. Intact extensor mechanism.~4. Adequate soft tissue envelope (no requirement for soft tissue coverage such as a muscle flap or skin graft)~5. Adequate bone stock for knee reconstruction~6. Medical fitness for staged knee reconstruction~Exclusion Criteria~1. Known Atypical infection (mycobacterial or fungal)~2. Extensor mechanism disruption~3. Inadequate soft tissue envelope requiring muscle flap or skin grafting~4. Inadequate bone stock (T3 or F3 by the Anderson Orthopaedic Research Institute (AORI) classification)~5. Medical status precluding staged knee reconstruction~6. Requirement for hinged knee reconstruction at the time of reimplantation~7. Pregnant women - for women of child bearing age, a negative pregnancy test will be needed prior to enrollment to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Static Antibiotic Spacer (Type: ACTIVE_COMPARATOR): Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
- Articulating Antibiotic Spacer (Type: ACTIVE_COMPARATOR): Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Automatic Adjustment for Asynchronies During Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>17 years~* Partial ventilatory support (SPONT mode) connected to Hamilton C1 model, irrespective of chronic restrictive or obstructive lung disease, categorized by RCexp (Expiratory time constant): restrictive (RCExp \<0.6); obstructive (RCExp \>0.9); normal (RCExp 0.6 - 0.9).~* Software version SW3.0.0 or superior and the IntelliSync+ software tool available in invasive and non-invasive ventilation.~* Presence of asyncronies in pressure and volume curves tracings of the ventilator.~* Signed informed content.~Exclusion Criteria:~* Pregnant~* On extracorporeal respiratory support (ECMO or ECCO2R)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Optimized ventilator settings to control and reduce the number of asynchronies
- Activated automatic detection and adjustment of asynchronies (Type: ACTIVE_COMPARATOR): Active mode of a mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PGD2 Formation in Vascular Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with existing CAD admitted for elective PTCA:~  1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or~ 2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or~ 3. No aspirin therapy at all~* Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA~* Patients with stable angina or positive stress tests scheduled for a cardiac catheterization~Exclusion Criteria:~* History of unstable diabetes (hgb A1c\>8 or FBS\> 200)~* Uncontrolled hypertension (SBP \> 180, DBP \>100)~* History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.~* Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- No Aspirin Treatment (Type: None): None
- 81 mg Aspirin Treatment (Type: None): None
- 325 mg Aspirin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues